{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":7,"sponsored":0,"items":[{"id":"n_iyyvbtawzlzkdmvuje3a","seq":1707241,"kind":"article","title":"Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?","url":"https://www.fool.com/coverage/better-buy/2026/10/04/amgen-vs-vertex-pharmaceuticals-which-biotech-stock-is-a-better-buy-in-2026?source=iedfolrf0000001","published":"2026-10-04T14:14:00Z","seen":"2026-10-04T18:09:18Z","lang":"en","source":{"id":"fool.com","name":"fool.com","domain":"fool.com","outlet":{"wikidata":"Q7752442","name":"The Motley Fool","type":"other","country":"US","designations":["dot-com company"]}},"via":"gdelt-gkg-english","topics":["economy","business","health","politics"],"authors":["Sara Appino"],"entities":[{"id":"Q470517","name":"Amgen","type":"org"},{"id":"Q2744099","name":"Vertex Pharmaceuticals","type":"org"}],"story":"st_iyyvbtawzlzkdmvuje3a","category":"economy-business","category_p":0.68,"sentiment":"neutral","tone":0.01,"political":0.02},{"id":"n_xx4xlzsyzalypjqesd6q","seq":1673647,"kind":"article","title":"Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Crosses Above 200 Day Moving Average – Time to Sell?","url":"https://www.tickerreport.com/banking-finance/13608326/vertex-pharmaceuticals-nasdaqvrtx-stock-price-crosses-above-200-day-moving-average-time-to-sell.html","published":"2026-10-04T13:20:42Z","seen":"2026-10-04T13:20:42Z","lang":"en","source":{"id":"tickerreport.com","name":"tickerreport.com","domain":"tickerreport.com"},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Joseph Griffin"],"entities":[{"id":"Q2744099","name":"Vertex Pharmaceuticals","type":"org"}],"story":"st_xx4xlzsyzalypjqesd6q","category":"economy-business","category_p":0.78,"sentiment":"neutral","tone":0.13,"political":0.02},{"id":"n_76al4wxp3p4wjqbdxvka","seq":1455239,"kind":"article","title":"Reviewing Spruce Biosciences (NASDAQ:SPRB) and Vertex Pharmaceuticals (NASDAQ:VRTX)","url":"https://www.tickerreport.com/banking-finance/13607396/reviewing-spruce-biosciences-nasdaqsprb-and-vertex-pharmaceuticals-nasdaqvrtx.html","published":"2026-10-03T00:35:25Z","seen":"2026-10-03T00:35:25Z","lang":"en","source":{"id":"tickerreport.com","name":"tickerreport.com","domain":"tickerreport.com"},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Max Byerly"],"entities":[{"id":"Q2744099","name":"Vertex Pharmaceuticals","type":"org"}],"story":"st_4iwlzioshninzgsfapfq","category":"economy-business","category_p":0.5,"category2":"health","sentiment":"neutral","tone":0.24,"political":0.02},{"id":"n_4iwlzioshninzgsfapfq","seq":1453877,"kind":"article","title":"Vertex Pharmaceuticals (NASDAQ:VRTX) vs. Spruce Biosciences (NASDAQ:SPRB) Head-To-Head Comparison","url":"https://www.dailypolitical.com/2026/10/02/vertex-pharmaceuticals-nasdaqvrtx-vs-spruce-biosciences-nasdaqsprb-head-to-head-comparison.html","published":"2026-10-03T00:24:14Z","seen":"2026-10-03T00:24:14Z","lang":"en","source":{"id":"dailypolitical.com","name":"dailypolitical.com","domain":"dailypolitical.com"},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Jeff Wilder"],"entities":[{"id":"Q2744099","name":"Vertex Pharmaceuticals","type":"org"}],"story":"st_4iwlzioshninzgsfapfq","category":"health","category_p":0.35,"category2":"economy-business","sentiment":"neutral","tone":0.2,"political":0.03},{"id":"n_2yizkg7kqn5xersjxala","seq":1263360,"kind":"article","title":"Financial Survey: Vertex Pharmaceuticals (NASDAQ:VRTX) & BeyondSpring (NASDAQ:BYSI)","url":"https://www.themarketsdaily.com/2026/10/02/financial-survey-vertex-pharmaceuticals-nasdaqvrtx-beyondspring-nasdaqbysi.html","published":"2026-10-02T04:35:14Z","seen":"2026-10-02T04:35:14Z","lang":"en","source":{"id":"themarketsdaily.com","name":"themarketsdaily.com","domain":"themarketsdaily.com"},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Sarita Garza"],"entities":[{"id":"Q2744099","name":"Vertex Pharmaceuticals","type":"org"}],"story":"st_2yizkg7kqn5xersjxala","category":"economy-business","category_p":0.75,"sentiment":"neutral","tone":-0.01,"political":0.01},{"id":"n_jtlqgur63m5ncvpfkg3a","seq":646562,"kind":"article","title":"2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.","url":"https://www.aol.com/articles/2-wall-street-analysts-think-093000000.html","published":"2026-09-29T09:30:00Z","seen":"2026-09-29T10:55:17Z","lang":"en","source":{"id":"aol.com","name":"aol.com","domain":"aol.com","outlet":{"wikidata":"Q27585","name":"AOL","type":"website","country":"US","designations":["business","company","enterprise","media company","online service provider","search engine","web portal"]}},"via":"gdelt-gkg-english","topics":["health","economy"],"authors":["AOL"],"entities":[{"id":"Q2744099","name":"Vertex Pharmaceuticals","type":"org"}],"story":"st_5mmumdywxtko6fh2ykfq","category":"economy-business","category_p":0.75,"sentiment":"positive","tone":0.49,"political":0.01},{"id":"n_ws3rzjkannkesz3zt3tq","seq":560847,"kind":"article","title":"Could Vertex Pharmaceuticals (VRTX)'s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?","url":"https://www.insidermonkey.com/news/could-vertex-pharmaceuticals-vrtxs-kidney-breakthrough-unlock-a-new-opportunity-for-maze-therapeutics-maze-1846012","published":"2026-09-29T02:15:00Z","seen":"2026-09-29T02:20:13Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Laiba Immad"],"entities":[{"id":"Q2744099","name":"Vertex Pharmaceuticals","type":"org"}],"story":"st_ws3rzjkannkesz3zt3tq","category":"economy-business","category_p":0.49,"category2":"health","sentiment":"positive","tone":0.27,"political":0.01}]}